| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
To develop seeds for development of medicines targeting RAGE for treatment of intractable pain, the present study first ascertained the involvement of RAGE in neuropathic and visceral pain using animal models. We then demonstrated that middle-molecular-weight-heparinylphenylalanine suppressed intractable pain possibly through selective blockade of RAGE. Our in silico analysis identified a small molecule compound that inhibits AGE-RAGE binding and is useful as a seed compound for novel RAGE blocker development. Together, our study identified both large and small molecules as RAGE blockers, which would be useful for pain treatment.
|
